Risperidone (Risperdal Consta)
Small molecule
Evidence outlook
Approved: Schizophrenia, Bipolar Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00253136 NCT00253136 · Schizophrenia, Psychotic Disorders This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo. Registry: NCT00253136 | 3 | Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score | Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. | Reliable signal | link ↗ |
View 2 more trials
NCT00210691 NCT00210691 · Schizophrenia The study was a nonrandomized, unblinded, single-arm follow-up involving 273 participants who had continued from or withdrawn from the prior double-blind RIS-USA-121 study. Because it was an open-label extension without a concurrent comparator and its results are not available, it provides limited evidence despite the relatively large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Incidence of adverse events; Injection site evaluation; Extrapyramidal Sympton Rating Scale (ESRS) results at each visit for at least 1 year; Clinical evaluations (physical exams, laboratory tests) will be conducted throughout trial". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT00210691 | 3 | Incidence of adverse events; Injection site evaluation; Extrapyramidal Sympton Rating Scale (ESRS) results at each visit for at least 1 year; Clinical evaluations (physical exams, laboratory tests) will be conducted throughout trial | Results not posted; external-source review pending | Weak signal | link ↗ |
NCT00132314 NCT00132314 · Schizoaffective Disorder, Schizophrenia The trial randomized 382 participants to injectable risperidone or oral antipsychotic treatment, but it was open-label and not blinded. Its hard clinical primary endpoint, hospitalization-free survival, was not statistically different between groups (hazard ratio 0.87, 95% CI 0.63–1.20; p=0.39), supporting moderate rather than strong evidence. Registry: NCT00132314 | 3 | Hospitalization-free Survival - Time to Event (From randomization until date of first re-hospitalization, assessed up to 24 months); Hazard Ratio for Hospitalization (24 months) 2009-09 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (13)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (29)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
Asenapine, Clozapine, Iloperidone (Fanapt), Lurasidone, Milsaperidone (VHX-896) and 17 more. Compare all 23 Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Risperidone (Risperdal Consta): this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | Partial signal | Featured results are non-efficacy only in this race | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Olanzapine / Samidorphan (Lybalvi) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziprasidone | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1042 | Phase 1(overall) | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify MyCite) | Discontinued | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
16 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.